<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVES: It is well established that various ENT disorders and symptoms may be a manifestation of <z:hpo ids='HP_0002020'>gastroesophageal reflux disease</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GERD</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>Erosive <z:hpo ids='HP_0100633'>esophagitis</z:hpo> is considered a rare finding in ENT patients and therefore upper gastrointestinal (GI) endoscopy is not recommended in the diagnostic work-up </plain></SENT>
<SENT sid="2" pm="."><plain>However, large prospective studies underscoring this policy are lacking </plain></SENT>
<SENT sid="3" pm="."><plain>The aim of the present study was to investigate the prevalence and severity of <z:hpo ids='HP_0100633'>esophagitis</z:hpo> in patients with suspected <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GERD</z:e>-related <z:hpo ids='HP_0011010'>chronic</z:hpo> ENT symptoms </plain></SENT>
<SENT sid="4" pm="."><plain>METHODS: Endoscopy was performed in 405 ENT patients with suspected <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GERD</z:e> and 545 typical <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GERD</z:e> patients </plain></SENT>
<SENT sid="5" pm="."><plain>The presence of erosive <z:hpo ids='HP_0100633'>esophagitis</z:hpo>, <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo>, <z:hpo ids='HP_0002036'>hiatal hernia</z:hpo>, <z:hpo ids='HP_0004398'>peptic ulcer</z:hpo>, and <z:hpo ids='HP_0005202'>Helicobacter pylori infection</z:hpo> on biopsies was determined and compared with the results of a symptom questionnaire </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: The prevalence of erosive <z:hpo ids='HP_0100633'>esophagitis</z:hpo> (52.3% vs 38.4%; p &lt; 0.05), mainly grade 1 (31.9% vs 22.7%; p &lt; 0.05), and of <z:hpo ids='HP_0004398'>peptic ulcer</z:hpo> (8.4% vs 4.3%; p &lt; 0.05) was significantly higher in patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GERD</z:e>-related ENT symptoms compared to typical <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GERD</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>Barrett's mucosa occurred in, respectively, 4.9% and 4.5% of the patients (NS) </plain></SENT>
<SENT sid="8" pm="."><plain><z:hpo ids='HP_0100633'>Esophagitis</z:hpo> prevalence was highest in patients with predominant cough and lowest in <z:e sem="disease" ids="C0017650" disease_type="Mental or Behavioral Dysfunction" abbrv="">globus pharyngeus</z:e> and throat symptoms </plain></SENT>
<SENT sid="9" pm="."><plain>The presence of <z:hpo ids='HP_0100633'>esophagitis</z:hpo> was associated with significantly higher rates of symptom relief during the first 8 wk of <z:chebi fb="0" ids="49200">proton pump inhibitor</z:chebi> (<z:chebi fb="4" ids="53266">PPI</z:chebi>) therapy </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSIONS: Patients with suspected <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GERD</z:e>-related ENT symptoms have a high prevalence of <z:hpo ids='HP_0100633'>esophagitis</z:hpo> and this is associated with better response to antisecretory therapy </plain></SENT>
</text></document>